IL24 and cancer: These results confirmed that creating a tripartite Ad.5, i.e., Ad.5-TCTV, did not compromise its ability to produce Ad5 E1A or the mda-7/IL-24 transgene following the infection of cancer cells, which were expressed at comparable levels as observed following infection with a bipartite Ad.5-CTV (Figure S1).